Post-ASH 2022 Multiple Myeloma Highlights

Free-to-attend Virtual Workshop by VJHemOnc featuring presentations & discussions
on selected multiple myeloma abstracts from the 64^th ASH Annual Meeting

Wednesday 18 January | 10:00 – 13:00 EST/15:00 – 18:00 GMT/16:00 – 19:00 CET

This event is for hematologists, researchers, nurses, and allied medical professionals only.
We will review your application and confirm your registration on submission.
By applying, you confirm that VJHemOnc can communicate with you regarding this event and share relevant hematology news.

Chairs:

María-Victoria Mateos, Salamanca, Spain
Saad Usmani, New York, USA
Charlotte Pawlyn, London, UK

Agenda (All times EST)

Introduction
10:00 – 10:45

Co-chairs : Maria-Victoria Mateos, Charlotte Pawlyn, Saad Usmani

Session 1: Newly diagnosed multiple myeloma
10:00 – 10:45

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
Francesco Maura (470)

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
Francesco Maura (646)

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial
Martin Kaiser (758)

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial
TBC (759)

Panel discussion 
10:20 – 10:45

Session 2: Bispecific mABs
10:45 – 12:05

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
TBC (97)

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase I/II Results from MonumenTAL-1
Ajai Chari (157)

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
Noopur Raje (158)

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
TBC (159)

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
Carmelo Carlo-Stella (161)

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase I First-in-Human Clinical Study
TBC (162)

A Phase I First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell–Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
Peter Voorhees (1919)

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
TBC (567)

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
Alexander Lesokhin (1924)

Panel discussion
11:45 – 12:05

Session 3: CAR-Ts

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
Saad Usmani (361)

Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase I, Multicenter, Open-Label Study
Luciano Costa (364)

Results from the First Phase I Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Luciano Costa (566)

Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
Bruno Paiva (868)

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
Paul Richardson (568)

Panel discussion
12:35 – 12:55

Challenging settings in MM
12:55 – 13:25

Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
Laura Notarfranchi (865)

Clinical Impact of Next Generation Flow in Bone Marrow versus Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
TBC (866)

Panel discussion

Smouldering multiple myeloma

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasonefor High Risk Smoldering Multiple Myeloma – Results of the Ascent Trial
Shaji Kumar (757)

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase III Ithaca Study
Maria-Victoria Mateos (3253) 

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Maria-Victoria Mateos (118)

Panel discussion
13:40 – 14:00

END OF WORKSHOP
14:00

This event is for hematologists, researchers, nurses, and allied medical professionals only.
We will review your application and confirm your registration on submission.
By applying, you confirm that VJHemOnc can communicate with you regarding this event and share relevant hematology news.